Market Overview

Why The Biotech Boom Is Still In The 1st Inning

Share:
Why The Biotech Boom Is Still In The 1st Inning
Related GILD
Deutsche Bank Casts Doubt On Pfizer's Rumored Takeover Approach To Bristol-Myers
Curing Disease Is Bad For Business: How Do Big Pharma Companies Continue Their Growth?
Why GlaxoSmithKline's 2017 Guidance Is Conservative (Seeking Alpha)
Related BDSI
15 Biggest Mid-Day Losers For Tuesday
Mid-Morning Market Update: Markets Open Higher; VeriFone Issues Weak Forecast

For This Week on Estimize, CEO Leigh Drogen is joined by Joe McCann, a buy-side biotech analyst and the Founder of Slingshot Insights.

Joe explains why he believes the biotech boom still has plenty of legs, and Leigh and Joe discuss how to value pharmaceutical stocks.

The discussion covers specific names including Gilead Sciences, Inc. (NASDAQ: GILD), BioDelivery Sciences International, Inc. (NASDAQ: BDSI), Retrophin Inc (NASDAQ: RTRX) and Auspex Pharmaceuticals Inc (NASDAQ: ASPX).

Image credit: Jeffrey Beall, Wikimedia

The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

Posted-In: Biotech BoomLong Ideas Trading Ideas Best of Benzinga

 

Related Articles (BDSI + ASPX)

View Comments and Join the Discussion!